NEW YORK, Nov. 10, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the NobleCon 19th Annual Emerging Growth Investor Conference in Boca Raton, FL.
To learn more about NobleCon and registration to attend or scheduling a one-on-one meeting with management please visit https://noblecon19.com/#companies.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.
Investor Contact:
LR Advisors LLC
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
www.hoththerapeutics.com
Phone: (678) 570-6791
| Last Trade: | US$0.83 |
| Daily Change: | -0.03 -3.84 |
| Daily Volume: | 55,135 |
| Market Cap: | US$5.750M |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
